TYMS and hematopoietic and lymphoid cell neoplasm: In summary, these data show that downregulation of TYMS expression with shRNA inhibits hematopoietic tumor growth in vivo and suggests that lowering TYMS levels enhanced tumor cell inhibition in vitro by pemetrexed or gemcitabine treatment.